KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Receivables - Accured: 2022-2025

Historic Revenue - Other for Arbutus Biopharma (ABUS) over the last 3 years, with Jun 2017 value amounting to $721,000.

  • Arbutus Biopharma's Revenue - Other rose 160.29% to $721,000 in Q2 2017 from the same period last year, while for Jun 2017 it was $1.8 million, marking a year-over-year decrease of 81.87%. This contributed to the annual value of $10.0 million for FY2017, which is 693.82% up from last year.
  • Latest data reveals that Arbutus Biopharma reported Receivables - Accured of $300,000 as of Q3 2025, which was up 200.00% from $100,000 recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Receivables - Accured ranged from a high of $600,000 in Q4 2022 and a low of $100,000 during Q2 2025.
  • Moreover, its 3-year median value for Receivables - Accured was $300,000 (2025), whereas its average is $409,091.
  • In the last 5 years, Arbutus Biopharma's Revenue - Other crashed by 99.80% in 2013 and then soared by 39,100.00% in 2014.
  • Quarterly analysis of 5 years shows Arbutus Biopharma's Revenue - Other stood at $5.0 million in 2013, then slumped by 79.69% to $1.0 million in 2014, then skyrocketed by 705.67% to $8.2 million in 2015, then slumped by 97.62% to $196,000 in 2016, then skyrocketed by 160.29% to $721,000 in 2017.
  • Its Revenue - Other was $721,000 in Q2 2017, compared to $217,000 in Q1 2017 and $196,000 in Q4 2016.